<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Nature Network - Recent topics from Society for Rational Drug Development (SRDD)</title>
    <description>The most recent forum topics from Society for Rational Drug Development (SRDD)</description>
    <link>http://network.nature.com/forum/http-network-nature-comgroupssrdd</link>
    <language>en-us</language>
    <ttl>40</ttl>
    <item>
      <title>Pre Clinical Tocicity (0 replies)</title>
      <description>
        <![CDATA[<p>The question relates to safety of drugs in human. Adequacy, correlation and predictability of pre-clinical toxicity studies are a challenge. It has multiple dimensions – among them the most important being drug safety during clinical development and post-marketing safety; it is also decisive in determining time, cost and failures of drug development. The questions that I put forward to open discussion:</p>


	<p>1.    What is the future of Pre-clinical development? <br />2.    How much should be in-vitro? <br />3.    What is the predictability of In-vivo? <br />4.    Can we replace in-vivo models with more in-vitro, to what extent? <br />5.    By doing this can we reduce the cost of development? <br />6.    Can we reduce time to development? <br />7.    What should be done to bring more predictability into Pre-clinical toxicity development?</p>]]>
      </description>
      <pubDate>Sat, 10 May 2008 03:00:53 -0000</pubDate>
      <link>http://network.nature.com/forums/http-network-nature-comgroupssrdd/1545</link>
      <dc:creator>Shushil Choubey</dc:creator>
      <guid>http://network.nature.com/forums/http-network-nature-comgroupssrdd/1545</guid>
    </item>
  </channel>
</rss>
